Physician profile
Maher Alesali
NPI 1801901509
$18,192.50
in general payments reported to CMS, 2019-2025
38 companies · $2,686 in 2025
The $2,686 reported for 2025 was more than what 81% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,163 · 2020: $2,104 · 2021: $2,750 · 2022: $2,676 · 2023: $2,628 · 2024: $2,184 · 2025: $2,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,384 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,383.54 |
| Education | $115.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,814.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,134.04 | 2019-2025 | Farxiga, Lokelma |
| Lilly USA, LLC | $1,903.63 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,804.02 | 2019-2025 | Jardiance, Synjardy |
| Corcept Therapeutics | $1,555.61 | 2019-2025 | Korlym |
| Dexcom, INC. | $1,347.12 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $1,000.50 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $684.11 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $630.64 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Amarin Pharma, INC. | $626.50 | 2020-2022 | |
| Amgen INC. | $608.12 | 2019-2025 | Tepezza, Evenity, Prolia |
| Merck Sharp & Dohme LLC | $550.60 | 2019-2023 | Steglatro, Belsomra, Januvia |
| Janssen Pharmaceuticals, INC | $500.35 | 2019-2022 | |
| Abbvie INC. | $455.66 | 2019-2021 | |
| Medtronic, INC. | $193.78 | 2021-2023 | Minimed 780g |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $184.38 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $165.07 | 2023-2025 | Yorvipath |
| Sequel Med Tech, LLC | $151.67 | 2025 | Twiist |
| Insulet Corporation | $141.48 | 2022-2025 | Omnipod |
| Shire North American Group INC | $124.39 | 2019 | |
| Horizon Therapeutics Plc | $113.33 | 2021-2022 | |
| Cequr Corporation | $108.78 | 2024-2025 | Cequr Simplicity |
| Radius Health, INC. | $48.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.74 | 2021 | |
| Esperion Therapeutics, INC. | $32.32 | 2023-2024 | Nexletol |
| Tandem Diabetes Care, INC. | $30.59 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sun Pharmaceutical Industries INC. | $30.31 | 2020 | |
| Ibsa Pharma INC. | $29.11 | 2022-2025 | Flector, Licart, Tirosint |
| Lifescan, INC. | $24.13 | 2019-2020 | |
| Cardiva Medical, INC. | $22.22 | 2025 | Cardiva Vascade 6/7f Vcs |
| Beta Bionics, INC. | $21.67 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amryt Pharma Holdings LTD | $19.92 | 2023 | Mycapssa |
| Kyowa Kirin, INC. | $18.64 | 2023 | |
| Nevro Corp. | $16.88 | 2024 | Senza |
| Novartis Pharmaceuticals Corporation | $15.24 | 2022 | |
| Acella Pharmaceuticals, LLC | $14.59 | 2025 | NP Thyroid 60 |
| Ultragenyx Pharmaceutical INC. | $14.10 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Alesali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.